ViiV Healthcare premier early data on INSTI VH184

GSK (GSK) announced that ViiV Healthcare, a company majority owned by GSK, with Pfizer (PFE) and Shionogi as shareholders, shared positive in vitro findings showing that an investigational integrase strand transfer inhibitor, INSTI, VH4524184, VH184, retained its antiviral activity and could be effective in countering second-generation INSTI resistance. Additional analysis presented of a phase I study showed pharmacokinetic and safety data supported further development of VH184. The findings are being presented at the 25th International AIDS Conference being held in Munich, Germany, from 22 – 26 July 2024. The presentation at AIDS 2024 is a combination of two separate analyses. The first evaluated VH184, in vitro, against more than 20 clinically derived HIV-1 viruses with mutations known to be associated with resistance to INSTIs. These viruses were identified from two phase III clinical trials of second-generation integrase inhibitors in treatment-experienced people living with HIV. Results from this analysis suggest VH184 has a resistance profile distinct from prior generations of INSTIs, showing that it was able to retain antiviral activity against clinically relevant mutations.